Skip to content

BIOMARIN PHARMACEUTICAL INC: 10-Q filed 2020-08-05

What BIOMARIN PHARMACEUTICAL INC reported in its quarterly report filed 2020-08-05 (fiscal Q2 2020): 48 published measures, 131 facts as tagged in accession 0001048477-20-000023.

This filing

Form
10-Q (quarterly report)
Filed
2020-08-05
Fiscal period
fiscal Q2 2020
Accession
0001048477-20-000023 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOMARIN PHARMACEUTICAL INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-06-305,302,110,000USD
At 2019-12-314,690,039,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-06-302,065,431,000USD
At 2019-12-311,567,658,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-06-303,236,679,000USD
At 2020-03-313,239,962,000USD
At 2019-12-313,122,381,000USD
At 2019-06-302,960,954,000USD
At 2019-03-312,936,627,000USD
At 2018-12-312,967,940,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-06-30818,900,000USD
At 2019-12-31437,446,000USD
At 2019-06-30307,577,000USD
At 2018-12-31493,982,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-29,183,000USD91
2020-01-01 to 2020-06-3052,198,000USD182
2019-04-01 to 2019-06-30-37,435,000USD91
2019-01-01 to 2019-06-30-93,908,000USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-06-3012,543,000USD182
2019-01-01 to 2019-06-30-79,206,000USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-06-3066,716,000USD182
2019-01-01 to 2019-06-3061,387,000USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2020-04-01 to 2020-06-30429,485,000USD91
2020-01-01 to 2020-06-30931,554,000USD182
2019-04-01 to 2019-06-30387,763,000USD91
2019-01-01 to 2019-06-30788,508,000USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-06-30544,017,000USD182
2019-01-01 to 2019-06-30-76,741,000USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-171,347,000USD182
2019-01-01 to 2019-06-30-30,808,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-06-30-1,668,511,000USD
At 2019-12-31-1,720,709,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2020-04-01 to 2020-06-30180,729,000shares91
2020-01-01 to 2020-06-30180,314,000shares182
2019-04-01 to 2019-06-30179,048,000shares91
2019-01-01 to 2019-06-30178,662,000shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2020-04-01 to 2020-06-30180,729,000shares91
2020-01-01 to 2020-06-30184,344,000shares182
2019-04-01 to 2019-06-30179,048,000shares91
2019-01-01 to 2019-06-30178,662,000shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-0.16USD/shares91
2020-01-01 to 2020-06-300.29USD/shares182
2019-04-01 to 2019-06-30-0.21USD/shares91
2019-01-01 to 2019-06-30-0.53USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-0.16USD/shares91
2020-01-01 to 2020-06-300.28USD/shares182
2019-04-01 to 2019-06-30-0.21USD/shares91
2019-01-01 to 2019-06-30-0.53USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-13,090,000USD91
2020-01-01 to 2020-06-306,881,000USD182
2019-04-01 to 2019-06-30-4,460,000USD91
2019-01-01 to 2019-06-30-944,000USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-06-301,010,917,000USD
At 2019-12-311,010,868,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-06-3091,956,000USD182
2019-01-01 to 2019-06-3082,590,000USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-40,945,000USD91
2020-01-01 to 2020-06-3064,016,000USD182
2019-04-01 to 2019-06-30-41,354,000USD91
2019-01-01 to 2019-06-30-95,305,000USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-06-302,647,566,000USD
At 2019-12-311,942,143,000USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-04-01 to 2020-06-308,048,000USD91
2020-01-01 to 2020-06-3014,963,000USD182
2019-04-01 to 2019-06-306,866,000USD91
2019-01-01 to 2019-06-3013,593,000USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-06-30813,302,000USD
At 2019-12-31932,503,000USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2020-06-30196,199,000USD
At 2019-12-31197,039,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2020-06-30381,215,000USD
At 2019-12-31377,404,000USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2020-01-01 to 2020-06-3050,000,000USD182
2019-01-01 to 2019-06-300USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2020-06-30743,852,000USD
At 2019-12-31680,275,000USD

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-04-01 to 2020-06-3097,967,000USD91
2020-01-01 to 2020-06-30209,341,000USD182
2019-04-01 to 2019-06-3077,436,000USD91
2019-01-01 to 2019-06-30166,618,000USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-04-01 to 2020-06-30175,412,000USD91
2020-01-01 to 2020-06-30362,707,000USD182
2019-04-01 to 2019-06-30160,754,000USD91
2019-01-01 to 2019-06-30322,912,000USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-04-01 to 2020-06-30182,139,000USD91
2020-01-01 to 2020-06-30324,396,000USD182
2019-04-01 to 2019-06-30185,641,000USD91
2019-01-01 to 2019-06-30369,232,000USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-06-30181,148,332shares
At 2019-12-31179,383,114shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-06-3030,050,000USD
At 2019-12-3120,164,000USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-06-3047,246,000USD
At 2019-12-3149,045,000USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-06-3049,897,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-06-301,602,750,000USD
At 2019-12-311,559,968,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-06-30591,833,000USD
At 2019-12-31549,100,000USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2020-06-30433,381,000USD
At 2019-12-31456,580,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-06-30135,852,000USD
At 2019-12-31122,009,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-06-30128,711,000USD
At 2019-12-3198,124,000USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2020-06-305,350,000USD
At 2019-12-3113,037,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-42,273,000USD91
2020-01-01 to 2020-06-3059,079,000USD182
2019-04-01 to 2019-06-30-41,895,000USD91
2019-01-01 to 2019-06-30-94,852,000USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-33,260,000USD91
2020-01-01 to 2020-06-3062,084,000USD182
2019-04-01 to 2019-06-30-39,790,000USD91
2019-01-01 to 2019-06-30-81,740,000USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-04-01 to 2020-06-3022,042,000USD91
2020-01-01 to 2020-06-3043,562,000USD182
2019-04-01 to 2019-06-3021,529,000USD91
2019-01-01 to 2019-06-3042,968,000USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-06-3051,180,000USD182
2019-01-01 to 2019-06-3048,771,000USD181

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-5,864,000USD182
2019-01-01 to 2019-06-30-10,083,000USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-06-304,154,000USD182
2019-01-01 to 2019-06-304,295,000USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2020-01-01 to 2020-06-303,712,000USD182
2019-01-01 to 2019-06-303,712,000USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-06-308,028,000USD182
2019-01-01 to 2019-06-3031,030,000USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-06-3046,298,000USD182
2019-01-01 to 2019-06-3033,119,000USD181

Inspect the source

Entity
BIOMARIN PHARMACEUTICAL INC / CIK 0001048477
Captured
2026-09-20T05:16:57.630Z
SEC response SHA-256
6bbba50e8b979af7a921a05188b4c51294e68e48d171ac508612bd4700bc19cd

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001048477.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))